Skip to main content
. 2020 Sep 10;15(22):2121–2135. doi: 10.1002/cmdc.202000391

Figure 8.

Figure 8

(a) Cell viability of BRCA‐deficient (UWB1.289) and BRCA‐proficient (UWB1.289+BRCA1) high grade serous ovarian cancer cells upon treatment with carboplatin (CPT) and olaparib (OPB) alone or in combination for 72 h, as determined by MTT assay. (b) Quantification of γH2AX foci formation as DNA damage marker upon treatments with carboplatin, olaparib or both for 72 h. (c) IC50 concentrations of cisplatin alone or in combination with 5 and 50 μmol/L of veliparib in nine different SCLC cells. (d) The tumour volume of H146 SCLC xenograft model following treatment with cisplatin and veliparib alone or in combination. Figure (a–b) reprinted (adapted) with permission from reference 119. Copyright 2018 American Chemical Society. Figure (c–d) adapted from reference 122 under the terms of the Creative Commons Attribution 3.0 Unported Licence (https://creativecommons.org/licenses/by/3.0/). Cancer Medicine published by John Wiley & Sons Ltd. © The Author 2014.